IL17A and Alzheimer disease: Compared to the SEMA4F low expression group, The SEMA4F high expression group activated multiple diseases of neurodegeneration, Parkinson’s disease, and Alzheimer’s disease while inhibiting the IL-17 signaling pathway, chemical carcinogenesis, protein-coupled receptor signaling pathway, axoneme assembly, and acute inflammatory response (Figures S6C, S6D).